Isoflavonoids from <i>Desmodium heterophyllum</i> Aerial Parts

Ha, Le Minh; Luyen, Nguyen Thi; Phương, Ngô Thị; Huyen, Do Thi; Hương, Lê Mai; Quan, Pham Minh; Hiep, Nguyen Tuan; Dat, Nguyen Tien

doi:10.1177/1934578x1801300612

Cited by 3 publications

(4 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The inconsistency of the inhibitory mechanism could result from the difference in the α-glucosidase type used in these studies. Additionally, this isoflavonoid was also reported to be more potent than acarbose in the α-amylase inhibition assay in two references [ 130 , 233 ]. On the other hand, the inhibitory potency of formononetin ( 167 ) towards α-glucosidase, is still controversial, with two out of three studies reporting it to be more effective than acarbose with micromolar potency [ 130 , 235 ] while the result from Jia et al showed a reverse pattern [ 65 ].…”

Section: Resultsmentioning

confidence: 99%

“…In a study by Ha et al (2018), dalbergioidin ( 168 ) was extracted from Desmodium heterophyllum aerial parts and evaluated for its anti-diabetic properties [ 233 ]. According to the results, this substance was found to exhibit stronger inhibition against α-glucosidase but weaker inhibition against α-amylase, in comparison with acarbose in the same experimental conditions [ 233 ]. Puerarin ( 169 ) is the only isoflavonoid glycoside included in our current review.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Flavonoids as dual-target inhibitors against α-glucosidase and α-amylase: a systematic review of in vitro studies

Lam,

Tran,

Pham

et al. 2024

Nat. Prod. Bioprospect.

View full text Add to dashboard Cite

Diabetes mellitus remains a major global health issue, and great attention is directed at natural therapeutics. This systematic review aimed to assess the potential of flavonoids as antidiabetic agents by investigating their inhibitory effects on α-glucosidase and α-amylase, two key enzymes involved in starch digestion. Six scientific databases (PubMed, Virtual Health Library, EMBASE, SCOPUS, Web of Science, and WHO Global Index Medicus) were searched until August 21, 2022, for in vitro studies reporting IC50 values of purified flavonoids on α-amylase and α-glucosidase, along with corresponding data for acarbose as a positive control. A total of 339 eligible articles were analyzed, resulting in the retrieval of 1643 flavonoid structures. These structures were rigorously standardized and curated, yielding 974 unique compounds, among which 177 flavonoids exhibited inhibition of both α-glucosidase and α-amylase are presented. Quality assessment utilizing a modified CONSORT checklist and structure–activity relationship (SAR) analysis were performed, revealing crucial features for the simultaneous inhibition of flavonoids against both enzymes. Moreover, the review also addressed several limitations in the current research landscape and proposed potential solutions. The curated datasets are available online at https://github.com/MedChemUMP/FDIGA. Graphical Abstract

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Flavonoids as dual-target inhibitors against α-glucosidase and α-amylase: a systematic review of in vitro studies

Lam,

Tran,

Pham

et al. 2024

Nat. Prod. Bioprospect.

View full text Add to dashboard Cite

show abstract

“…Peonidin 3-O-glucoside was detected in TN50E, TNW70M and TNW80M conditions and has been previously described to be as efficient (IC 50 = 192.3 μg/mL) as acarbose (IC 50 = 180.2 μg/mL) in inhibiting rat intestinal α-glucosidase [ 73 ]. Dalbergioidin, an isoflavanone that was abundant in TNW70M and TNW80M fractions has been found to efficiently inhibit α-glucosidase (IC 50 = 412.6 μM) compared to acarbose (IC 50 = 671.4 μM) [ 74 ]. The xanthone garbogiol has also been found to exhibit considerable α-glucosidase inhibition (IC 50 = 21.2 μM) compared to acarbose (IC 50 = 214.5 μM) [ 75 ].…”

Section: Resultsmentioning

confidence: 99%

In vitro α-glucosidase inhibitory activity of Tamarix nilotica shoot extracts and fractions

et al. 2022

View full text Add to dashboard Cite

α-glucosidase inhibitors represent an important class of type 2 antidiabetic drugs and they act by lowering postprandial hyperglycemia. Today, only three synthetic inhibitors exist on the market, and there is a need for novel, natural and more efficient molecules exhibiting this activity. In this study, we investigated the ability of Tamarix nilotica ethanolic and aqueous shoot extracts, as well as methanolic fractions prepared from aqueous crude extracts to inhibit α-glucosidase. Both, 50% ethanol and aqueous extracts inhibited α-glucosidase in a concentration-dependent manner, with IC50 values of 12.5 μg/mL and 24.8 μg/mL, respectively. Importantly, α-glucosidase inhibitory activity observed in the T. nilotica crude extracts was considerably higher than pure acarbose (IC50 = 151.1 μg/mL), the most highly prescribed α-glucosidase inhibitor on the market. When T. nilotica crude extracts were fractionated using methanol, enhanced α-glucosidase inhibitory activity was observed in general, with the highest observed α-glucosidase inhibitory activity in the 30% methanol fraction (IC50 = 5.21 μg/mL). Kinetic studies further revealed a competitive reversible mechanism of inhibition by the plant extract. The phytochemical profiles of 50% ethanol extracts, aqueous extracts, and the methanolic fractions were investigated and compared using a metabolomics approach. Statistical analysis revealed significant differences in the contents of the crude extracts and fractions and potentially identified the molecules that were most responsible for these observed variations. Higher α-glucosidase inhibitory activity was associated with an enrichment of terpenoids, fatty acids, and flavonoids. Among the identified molecules, active compounds with known α-glucosidase inhibitory activity were detected, including unsaturated fatty acids, triterpenoids, and flavonoid glycosides. These results put forward T. nilotica as a therapeutic plant for type 2 diabetes and a source of α-glucosidase inhibitors.

show abstract

“…D. gangeticum has been used for the treatment of asthma, stomatitis, arthritis, eczema, or some other diseases [1]. Previous studies proved the contents of flavonoids, alkaloids, and sterols in D. gangeticum with hepatoprotective, antiinflammatory, antileishmanial, immunomodulatory, cardioprotective, antinociceptive wound healing, antidiabetic, and antiulcer activities [3][4][5][6]. Nitric oxide (NO) has been known to involve in the regulation of various physiological processes in mammals and the overproduction of NO is responsible for the pathological development of inflammation, cancer, and diabetes [7,8].…”

Section: Introductionmentioning

confidence: 99%

A New Megastigmane Glucoside and Other Constituents from Desmodium gangeticum

Dang

Giang

Ngo

et al. 2020

Journal of Chemistry

View full text Add to dashboard Cite

A new megastigmane glycoside, gangeticoside (1), and three known compounds leonuriside A (2), methyl benzoate 2-O-β-D-glucopyranoside (3), and tortoside A (4) were isolated from the aerial part of Desmodium gangeticum. Their structures were determined by 1D and 2D NMR spectra. The isolated compounds were evaluated for their inhibitory effect on NO production in LPS-stimulated RAW264.7 cells. Among them, compounds 1, 2, and 3 exhibited strong effect with the IC50 values of 22.3, 15.6, 7.3 μM, respectively.

show abstract

Isoflavonoids from Desmodium heterophyllum Aerial Parts

Cited by 3 publications

References 5 publications

Flavonoids as dual-target inhibitors against α-glucosidase and α-amylase: a systematic review of in vitro studies

Flavonoids as dual-target inhibitors against α-glucosidase and α-amylase: a systematic review of in vitro studies

In vitro α-glucosidase inhibitory activity of Tamarix nilotica shoot extracts and fractions

A New Megastigmane Glucoside and Other Constituents from Desmodium gangeticum

Contact Info

Product

Resources

About